Missense mutations of ACTA1 cause dominant congenital myopathy with cores


Conventional congenital myopathies (CM) are neuromuscular disorders classified by characteristic histopathological findings in muscle fibers. Areas devoid of oxidative enzyme activity (core lesions) are pathologic hallmarks of autosomal dominant or recessive central core disease (CCD; MIM 117000) and multifascicular core disease (MmD; MIM 255320). While large and solitary cores in the center and along the entire length of muscle fibers are considered typical for CCD and multiple smaller cores within muscle fibers define MmD, this classic histological distinction is complicated by the marked histological variability of core lesions. Minicores and central cores have been detected concomitantly as well as separately in successive muscle biopsy specimens of single patients and in myofibers of different affected family members. So far, mutations in three gene loci have been associated with core myopathies: ryanodine receptor-1 gene (RYR1; MIM 180901) in both CCD and MmD, selenoprotein N-1 gene (SEPN1; MIM 606210) in MmD, and myosin heavy chain-7 gene (MYH7; MIM 160760) in CCD.

The increased number of identified genetic defects in patients with thoroughly characterised CM phenotypes has disclosed both marked phenotype and genotype variability and considerable disease overlap. The finding of cores together with rod-like lesions in muscle biopsy specimens of patients with RYR1 mutations and skeletal muscle alpha-actin gene (ACTA1; MIM 102610) mutations and in families showing linkage to chromosome 15q21–q23 indicate a phenotype overlap of core diseases and nemaline myopathy (MIM 256030). Likewise, the concurrent occurrence of cores and fingerprint bodies suggests an overlap with fingerprint body myopathy (MIM 305550). These findings and an absence of mutations in established gene loci in patients with clinical and histological hallmarks of core myopathy promise further genetic heterogeneity.

ACTA1 mutations are known to cause three congenital myopathies: nemaline myopathy, actin myopathy (MIM 102610), and intranuclear rod myopathy. Here, we are the first to report on ACTA1 mutations which cause a fourth type of CM in two families, an autosomal dominant congenital myopathy with cores.

METHODS
Patients
We studied 14 patients and 27 unaffected relatives of two unrelated families of German (family 1) and Chinese (family 2) descent after written informed consent was obtained. The diagnosis of core myopathy was established on the basis of clinical and histopathological criteria. Analysis of muscle specimens was performed in five patients (patients III:9, III:12, and IV:11 in family 1, and patients II:2 and III:2 in family 2; fig 1).

Linkage analysis
Genomic DNA was isolated from peripheral blood lymphocytes according to standard procedures. Microsatellite analysis was performed with sequence specific forward and reverse primers and universal fluorescent labeled M13 labelled primers by standard semi-automated methods using an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). We confirmed the order of microsatellite markers flanking RYR1, SEPN1, MYH7, and ACTA1 in published human linkage maps (Ensembl Genome Browser, Human Genome Browser Gateway, and Entrez Genome View) and amplified four to six markers for each gene locus.

Genome-wide linkage scan
We performed genome-wide linkage analysis using the early access GeneChip Human Mapping 10K Array and Assay Kit from Affymetrix (Santa Clara, CA, USA) with 11 560 single

Key points
• Central core and minicore diseases are clinically and genetically heterogeneous, autosomal dominant or recessive congenital myopathies characterised by muscle weakness and areas devoid of oxidative activity (cores) within myofibers. So far, mutations in the ryanodine receptor-1 gene (RYR1), the selenoprotein N-1 gene (SEPN1), and the myosin heavy chain-7 (MYH7) gene have been identified as a cause of core myopathies.
• Here, we are the first to report on an autosomal dominant "core only" myopathy caused by missense mutations of the skeletal muscle alpha-actin gene (ACTA1) in two families.
• Patients of both families showed a rather mild and non-progressive course of skeletal muscle weakness. Interestingly, the myopathy was accompanied by adult onset hypertrophic cardiomyopathy and respiratory failure in one family. Histologically, cores were detected in the muscle fibers of at least one patient in each family, while nemaline bodies or rods and actin filament accumulation were absent.
• These findings establish ACTA1 mutations as a new cause of dominant congenital myopathy with cores and describe a new clinicopathological phenotype for ACTA1.
nucleotide polymorphisms (SNPs). For quality control and data conversion, a computer program was written. We verified the relationship of family members with the GRR program and the gender of individuals through the analysis of X linked markers for heterozygous genotypes. PedCheck was used for detection of Mendelian errors. With Merlin, we identified unlikely genotypes and subsequently removed all erroneous genotypes from the data set.

### Sequencing analysis

All six protein encoding exons of ACTA1 (GenBank accession number NM_001100) and adjacent exon-intron boundaries were sequenced in patient III:9 (family 1), patient II:2 (family 2), and one control. We amplified and sequenced exons 2 and 7 in all members of families 1 and 2, respectively, and also in 50 controls. Primer sequences designed for amplification of exons 2 and 7 were 5'CCCTGCCGGCTGA GACCTCTG-3' (forward), 5'GCAGCCCTGACCTGTCGTTG-3' (reverse) and 5'AGCACCATTAGATCAAGG-3' (forward), 5'CTGTGTCAGTTTAGATGCGCAGC-3' (reverse), respectively. PCR cycling conditions and further primer sequences used for linkage analysis and sequencing are available from the authors on request.

### Restriction fragment analysis

To confirm the 1110A→C mutation that creates a novel PauI site in family 2, a 372 bp fragment containing ACTA1 exon 7 was amplified by PCR using the following primer set: 5'AGCACCATTAGATCAAGG-3' (forward) and 5'CTGTGTCAGTTTAGATGCGCAGC-3' (reverse). PauI restriction digest of the mutated allele releases two fragments of 256 and 116 bp, whereas the wild type sequence remains uncut.

### RESULTS

#### Clinical and histological features

All patients reported a clinical onset of proximal or generalised muscle weakness in early childhood. Disease severity showed a slight intra- and interfamilial variation with usually mild and non-progressive symptoms such as moderate muscle weakness with delayed motor milestones.
<table>
<thead>
<tr>
<th>Patient</th>
<th>Family</th>
<th>Sex</th>
<th>Current age (years)</th>
<th>Clinical onset</th>
<th>Delayed motor milestones</th>
<th>Muscle weakness distribution</th>
<th>Facial weakness</th>
<th>Cardiomyopathy</th>
<th>Respiratory insufficiency</th>
<th>Skeletal abnormalities</th>
<th>Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>II:2</td>
<td>M</td>
<td>73</td>
<td>7 years: slow gait</td>
<td>–</td>
<td>Mild: global</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Stable</td>
</tr>
<tr>
<td>II:4</td>
<td>F</td>
<td>70</td>
<td>8 years: slow gait</td>
<td>–</td>
<td>Moderate: proximal UE</td>
<td>Mild</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Mild scoliosis</td>
<td>Improvement</td>
</tr>
<tr>
<td>II:6</td>
<td>F</td>
<td>66</td>
<td>5 years: slow gait</td>
<td>–</td>
<td>Moderate: global</td>
<td>Mild</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Mild scoliosis</td>
<td>Stable</td>
</tr>
<tr>
<td>II:8</td>
<td>F</td>
<td>62</td>
<td>7 years: slow gait</td>
<td>–</td>
<td>Mild: proximal UE, trunk</td>
<td>Moderate</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Mild scoliosis, high arched palate</td>
<td>Improvement</td>
</tr>
<tr>
<td>III:3</td>
<td>M</td>
<td>41</td>
<td>8 years: slow gait</td>
<td>–</td>
<td>Mild: proximal E, trunk</td>
<td>Moderate</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Mild scoliosis, genu varum</td>
<td>Stable</td>
</tr>
<tr>
<td>III:9</td>
<td>F</td>
<td>39</td>
<td>Infancy</td>
<td>Walked at 3 years</td>
<td>Moderate: proximal E, trunk</td>
<td>Moderate</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Moderate scoliosis, high arched palate</td>
<td>Stable</td>
</tr>
<tr>
<td>III:12</td>
<td>F</td>
<td>39</td>
<td>4 years: slow gait</td>
<td>–</td>
<td>Mild: proximal LE</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Mild scoliosis</td>
<td>Stable</td>
</tr>
<tr>
<td>IV:3</td>
<td>F</td>
<td>15</td>
<td>6 years: slow gait</td>
<td>–</td>
<td>Mild: proximal LE</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Mild scoliosis, moderate scapular winging, genu valgum</td>
<td>Stable</td>
</tr>
<tr>
<td>IV:11</td>
<td>M</td>
<td>13</td>
<td>7 years: waddling gait</td>
<td>–</td>
<td>Mild: proximal LE</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Funnel chest</td>
<td>Stable</td>
</tr>
<tr>
<td>IV:13</td>
<td>M</td>
<td>11</td>
<td>2 years: slow gait and severe intoeing</td>
<td>Walked at 2 years</td>
<td>Mild: proximal LE, post-exertional myalgia</td>
<td>Mild</td>
<td>–</td>
<td>–</td>
<td>9 years: global, nocturnal respiratory support</td>
<td>Joint hyperlaxity, femoral anteverision, internal tibial torsion, scapular winging, high arched palate</td>
<td>Improvement</td>
</tr>
<tr>
<td>Family 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II:6</td>
<td>M</td>
<td>49</td>
<td>Infancy</td>
<td>Walked at 6 years</td>
<td>Mild: global; LE=UE</td>
<td>Mild</td>
<td>Hypertrophic cardiomyopathy</td>
<td>49 years: global, nocturnal respiratory support</td>
<td>Funnel chest, flat feet</td>
<td>Stable</td>
<td></td>
</tr>
<tr>
<td>II:2</td>
<td>M</td>
<td>35</td>
<td>Infancy</td>
<td>Walked at 5 years</td>
<td>Mild: global</td>
<td>Mild</td>
<td>Hypertrophic cardiomyopathy</td>
<td>32 years: global, nocturnal respiratory support</td>
<td>Joint hyperlaxity, flat feet, scoliosis, funnel chest, high arched palate</td>
<td>Stable</td>
<td></td>
</tr>
<tr>
<td>III:4</td>
<td>F</td>
<td>5</td>
<td>Infancy</td>
<td>Walked at 2 years</td>
<td>Mild: LE</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Joint hyperlaxity, high arched palate</td>
<td>Stable</td>
</tr>
<tr>
<td>III:2</td>
<td>M</td>
<td>18</td>
<td>Infancy</td>
<td>–</td>
<td>Mild: global</td>
<td>Mild</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Funnel chest, flat feet</td>
<td>Stable</td>
</tr>
</tbody>
</table>

Abbreviations: female (F), male (M), lower extremities (LE), upper extremities (UE).
difficulties climbing stairs and running, facial weakness, slowness of movements, post-exertional myalgia in childhood, and skeletal abnormalities (fig 2; table 1). Index patient IV:11 of family 1 presented at the age of 7 years with a non-progressive, mild, and proximal muscle weakness (waddling gait, difficulties getting up from supine position; fig 2A). Also, he exhibited a funnel chest, hyperlordosis of his lumbar spine, and distal joint hyper laxity on physical examination. His mother (III:9) was affected more severely; she had delayed motor milestones and moderate proximal muscle and facial weakness. Similar to other patients of family 1, she complained of slowness in movements. She was unable to run, but could walk for hours.

Two patients of family 2 (II:2 and II:6; fig 1B) developed adult onset hypertrophic cardiomyopathy and respiratory insufficiency. Patient II:2, currently 35 years of age, had delayed motor milestones and started walking at the age of 5 years. He was never able to run, but worked full time in a restaurant. He did not seek medical assistance until the age of 32 years, when a global respiratory insufficiency developed that now requires nocturnal ventilation. On examination, he showed mild, symmetrical, distal, and proximal muscular weakness, a high arched palate, planus feet, a funnel chest, marked scoliosis, and distal joint laxity. CK levels were normal. Hypertrophic cardiomyopathy was detected by echocardiography. His older brother (II:6), now 49 years of age, shows a similar clinical picture with a milder clinical course that required nocturnal ventilation only recently. Cardiomyopathy was detected by echocardiography at age 47, that is, 2 years before he developed clinical signs of respiratory insufficiency. Initially, only thickening of the septum and the left ventricular wall was seen. Recently, additional signs of right ventricular dilatation and heart failure were detected that improved under ventilation.

Histologically and ultrastructurally, myopathic changes and core lesions were detected in skeletal muscle biopsy specimens of both families; nemaline rods were absent and there was no accumulation of actin filaments. ATPase staining and staining with antibodies to slow myosin proteins including myosin heavy chain, which previously has been selected as the most promising candidate gene considering the following: (i) alpha-actin interacts with a variety of proteins including myosin heavy chain, which previously has

members of both families revealed differences in size, number, and appearance. In family 1, primarily singular core lesions were found in muscle specimens of two patients (quadriceps femoris muscle). Cores were unstructured, poorly circumscribed, central, or eccentric; they were rather broad but did not run along the entire long axis of muscle fibers and are thus typical neither of CCD nor of MmD (fig 3). Immunocytochemical staining of muscle biopsy sections from patients and controls showed a normal uniform honeycomb staining pattern of actin. In family 2, two biopsies of patient II:2 were taken at the age of 32 (biceps brachii muscle) and 33 years (lateral gastrocnemius muscle), and one biopsy specimen of patient III:2 was taken at the age of 14 years (quadriceps femoris muscle). Histologically, cores were detected in both biopsy samples of patient II:2. Similarly to family 1, core lesions were poorly circumscribed, both central and eccentric. In contrast to family 1, cores were very small, and multiple cores occurred in a single muscle fiber. Ultrastructurally, these minicore-like lesions appeared as circular zones containing contractile filaments, but were devoid of mitochondria (fig 3). Interestingly, myopathologic findings in the muscle biopsy specimen of patient III:2 were unspecific and cores were not found. A slight preponderance of type I fibers was noted on ATPase stains, but the sizes of type I and type II fibers were within the normal range (data not shown).

Genetic results

Linkage to the three core disease loci RYR1, MYH7, and SEPN1 reported at the time of our study was excluded in both families. Therefore, we performed genome-wide linkage analysis in family 1 using GeneChip Human Mapping 10K Array and Assay Kit from Affymetrix. Genotyping was performed in 10 affected and six unaffected members of family 1, and a maximum multi-point LOD score of 3.31 was calculated around SNP rs54108 on chromosome 1q42. We defined a critical disease interval of about 4.6 Mbp, equivalent to approximately 7 Mbp, by haplotype reconstruction. ACTA1 was selected as the most promising candidate gene considering the following: (i) alpha-actin interacts with a variety of proteins including myosin heavy chain, which previously has...
showed Z disk lesions (G; magnification 6). In family 2, cores were significantly smaller and more frequent in NADH-TR staining, especially in the majority of fibers in a single cross section. In muscle specimens of family 2, minicores were surrounded by normal sarcomeres. These cores do not run along the myofilament structure within these lesions (unstructured cores) and 50 control individuals, as well as the location of the two mutations at highly conserved amino acid positions (fig 4).

DISCUSSION

In this study, we have identified mutations of ACTA1 as a cause of autosomal dominant core myopathy in two families of different ethnic origin. So far, ACTA1 mutations have been reported to cause three forms of congenital myopathy (nemaline myopathy, intranuclear rod myopathy, actin myopathy), but cores have not been described as exclusive histopathological features in these disorders. Conversely, “core only” myopathies have been caused by mutations in three different genes (RYR1, SEPN1, MYH7), but not in ACTA1.

Among patients with ACTA1 mutations, the severe form of nemaline myopathy with early onset muscle weakness, rapid course, and respiratory insufficiency is most frequently reported. A benign phenotype similar to that found in our patients is rare, but has been reported.13–15 Similarly, the slowness of movements of our patients with core myopathy is an unusual feature of ACTA1 diseases, but has been described in single patients with core rod myopathy and RYR1 mutations or linkage to chromosome 15q21–q23.13–14

Since, to the best of our knowledge, cardiomyopathies have not been reported in ACTA1 myopathies, the hypertrophic cardiomyopathy detected in family 2 is of particular interest. We cannot exclude that the cardiomyopathy detected in patient II:2 is secondary to a longstanding and impaired respiratory function, since his heart function was first assessed after respiratory insufficiency had developed. However, echocardiography of patient II:6 showed signs of cardiomyopathy 2 years prior to respiratory insufficiency. Both the left ventricle and the septum were affected at this time, a finding which is not expected for cardiomyopathies due to respiratory failure. Moreover, ACTA1 accounts for approximately 20% of the total amount of actin in healthy human myocardium.16 Mutations in the cardiac alpha-actin gene (ACTC; MIM 102540), which encodes the predominant actin isoform of mature myocytes (~80%), can cause familial hypertrophic and dilated cardiomyopathy.17–21 Thus, even though cardiomyopathy is not an established feature of ACTA1 myopathies and one actin isoform has been suggested to partially compensate for the other,16 ACTA1 mutations could affect cardiac and skeletal muscle simultaneously or to mutations in other genes causing nemaline myopathy or core disease. Histopathological studies of cardiac muscle, if they become available, may clarify this finding.

The histopathological phenotype of skeletal muscle biopsy specimens of patients with dominant core myopathy caused by ACTA1 mutations is variable, but clearly different from previously described actinopathies. It combines characteristic features of atypical central core disease with those found in atypical minicore disease and shows similarities to core-like areas reported in addition to typical nemaline rods for patients with ACTA1 mutations or linkage to chromosome 15q21–23.13–14 Moreover, cores were absent in the quadriceps femoris muscle of one patient of family 2 biopsied at 14 years of age. Since this biopsy showed only rather unspecific features, the given molecular diagnosis probably would have been missed in a sporadic case. Thus, mutations in the ACTA1 gene should be considered in patients with a congenital myopathy and an unspecific histopathological phenotype.

Neither of the ACTA1 mutations reported in this study have been described previously in humans or mice. Therefore, we can only speculate about the functional consequences of these mutations. Interestingly, the mutation detected in family 1 (110G>T) causes an amino acid exchange of the
first amino acid of the mature actin protein (D1Y). In humans, alpha-actin precursor protein is transformed into mature alpha-actin by co- and posttranslational acetylation and cleavage of the first two amino acids methionine and cysteine and subsequent acetylation of the then initial residue aspartic acid. The highly conserved NH₂-terminal amino acid sequence is regarded as essential for this unique processing procedure. So far, the impact of amino acid changes in this part of the protein could be exclusively inferred from studies that include site directed mutagenesis, antibodies directed towards the first amino acids of actin, and chemical crosslinking experiments. In vitro inhibition of act acetylation leads to the accumulation of the actin precursor in Drosophila. Moreover, the interaction of alpha-actin with other proteins may be disturbed by the missense mutation D1Y, since the NH₂ terminus is considered to be a major binding site for interacting proteins. The binding of myosin heads affects the generation of force as demonstrated in studies using NH₂-terminal site directed mutagenesis of Dictyostelium actin.

The mutation detected in family 2 (1110A→C) causes an amino acid exchange at position 334 of the mature protein (E334A). Previously, a mutation affecting position 336 of alpha-actin has been described in intranuclear rod myopathy. This residue lies within the hinge and forms part of the nucleotide binding pocket. Accordingly, E334A may also interfere with nucleotide binding and exchange either directly or indirectly. These effects and others including protein stability, polymerisation, and degradation can reduce force generation during muscle contraction and thus contribute to the phenotype of ACTA1 core myopathy.

The description of ACTA1 core myopathy expands the phenotype spectrum of actinopathies and adds to the genetic heterogeneity of core myopathies. The genetic and histomorphological overlap between core disease and nemaline myopathy highlights the fact that core lesions are not pathognomonic of a specific congenital myopathy. The mechanisms through which mutations alternatively cause CCD, MmD, nemaline myopathy, actin myopathy, or intranuclear rod myopathy remain to be identified.

ACKNOWLEDGEMENTS

The authors thank the patients and their families for participation in this study and acknowledge the help and critical comments of Petra Mitzscherling, Kerstin Neubert, Mia Hövmoller, Lars Edström, and Christoph Hübner. AMK, AH, DP, and HL are members of the German Network on Muscular Dystrophies (MD-NET, 01GM0302).

ELECTRONIC-DATABASE INFORMATION

Electronic-database information is as follows: Ensembl Genome Browser: www.ensembl.org; Human Genome Browser Gateway: http://www.genome.ucsc.edu/cgi-bin/hgGateway; Entrez Genome View: http://www.ncbi.nlm.nih.gov/mapview/

Authors’ affiliations
A M Kaindl, K Koehler, A Huebner, Children’s Hospital, Technical University Dresden, Dresden, Germany
A M Kaindl, Department of Neuropediatrics, Charité, University Medical School Berlin, Berlin, Germany
P Nürnberg, Institute of Medical Genetics, Charité, University Medical School Berlin, Berlin, Germany
G Stoltenburg-Didinger, Institute of Neuropathology, Charité, University Medical School Berlin, Berlin, Germany
S Krause, D Pongratz, H Lochmüller, Department of Neurology, Friedrich-Baur Institute, and Gene Center, Ludwig-Maximilians-University, Munich, Germany
H-H Goebel, Department of Neuropathology, Johannes Gutenberg University of Mainz, Mainz, Germany
REFERENCES


